Real‐world persistence of multiple sclerosis disease‐modifying therapies
(2024)
Journal Article
Tallantyre, E. C., Dobson, R., Froud, J. L. J., St John, F. A., Anderson, V. M., Arun, T., …Robertson, N. P. (in press). Real‐world persistence of multiple sclerosis disease‐modifying therapies. European Journal of Neurology, Article e16289. https://doi.org/10.1111/ene.16289
Background and purpose: Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real‐world rates of persistence on disease‐modifying therapies (DMTs) for p... Read More about Real‐world persistence of multiple sclerosis disease‐modifying therapies.